Sleep Apnea Benefits Added to Weight Loss Drug Mounjaro’s Label
The European Medicines Agency (EMA) has granted Eli Lilly permission to update the label for its weight loss drug, Mounjaro, to include benefits for treating sleep apnea.
The company is seeking European Union approval for the broader use of Mounjaro in treating moderate to severe obstructive sleep apnea (OSA) in patients with obesity.
According to the EMA, Mounjaro does not require separate approval for treating sleep apnea, emphasizing the close association between this disorder and obesity.
A 2019 study published in The Lancet estimates that approximately 1 billion people worldwide suffer from obstructive sleep apnea.
End of Message
Feel free to share this content with attribution to The World of Health and Medicine.
